Provide comprehensive, point‑wise notes on oxygen delivery devices, covering indications, flow rates, FiO₂ ranges, advantages, disadvantages, humidification, monitoring, and escalation for exam preparation.

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Oxygen Delivery Devices: Comprehensive Exam Notes

Low-Flow Oxygen Delivery Systems

Nasal Cannula

Nasal cannula is the first-line oxygen delivery device for most patients requiring supplemental oxygen. 1

Flow Rates and FiO₂ Delivery

  • Flow range: 1–6 L/min delivering approximately 24–50% FiO₂ 2
  • Each additional liter increases FiO₂ by approximately 3–4% 2, 3
  • At 2 L/min: FiO₂ ranges from 24–35% (wide individual variation) 2
  • At 5 L/min: approximately 40% FiO₂ 4
  • The actual FiO₂ cannot be precisely predicted due to variations in respiratory rate, tidal volume, and breathing pattern 2, 4

Advantages

  • Superior patient comfort compared to masks 1, 2
  • Can be worn during meals and speech 1, 2
  • Less likely to be removed by patients 1
  • No risk of CO₂ rebreathing 2, 4
  • Lower inspiratory resistance than face masks 1
  • More cost-effective 4
  • No claustrophobic sensation 4

Disadvantages

  • Unpredictable FiO₂ delivery makes it unsuitable when exact oxygen concentration is required (e.g., calculating A-a gradient) 2, 4
  • Nasal irritation or soreness, especially at flow rates >4 L/min 4
  • Reduced effectiveness with severe nasal congestion 4
  • Flow rates must be adjusted based on pulse oximetry and arterial blood gas results 2, 4

Clinical Pearls

  • Mouth breathing does NOT reduce effectiveness—it may actually result in the same or higher inspired oxygen concentration 4, 3
  • Most centers advocate humidification, although evidence for non-heated humidification is lacking 1
  • For ambulatory patients, low-flow 100% oxygen is easily adjusted by caregivers to match activity levels 1

Simple Face Mask

Flow Rates and FiO₂ Delivery

  • Flow range: 5–10 L/min delivering 40–60% FiO₂ 2, 3
  • CRITICAL: Never use flow rates below 5 L/min—this causes dangerous CO₂ rebreathing and increased inspiratory resistance 2

Disadvantages

  • Less comfortable than nasal cannula 2
  • Must be removed for meals 2
  • Less preferred than nasal cannula for medium-concentration oxygen therapy 2

Venturi (Fixed-Performance) Masks

Venturi masks are mandatory for patients requiring precise FiO₂ control, particularly those at risk of hypercapnic respiratory failure. 1, 2

Available Concentrations

  • Fixed FiO₂ options: 24%, 28%, 31%, 35%, 40%, and 60% 1, 2
  • Each concentration requires manufacturer-specified flow rates 2

Indications

  • Patients at risk of hypercapnic respiratory failure (COPD, obesity hypoventilation syndrome) 1, 2
  • Patients with high resting respiratory rate (>30 breaths/min) 1, 2
  • Confused or cognitively impaired patients to prevent inadvertent flow-rate errors 1, 2

Critical Adjustment

  • For respiratory rate >30 breaths/min, increase flow rate above the minimum specified to maintain intended FiO₂ 1, 2

Target Oxygen Saturation

  • For hypercapnic-risk patients: target SpO₂ 88–92% (not 94–98%) 2, 4
  • Use 24% or 28% Venturi mask or nasal cannula at 1–2 L/min 2

High-Flow Oxygen Delivery Systems

High-Flow Nasal Cannula (HFNC)

HFNC is indicated for acute hypoxemic respiratory failure and post-extubation respiratory support, NOT for routine home oxygen therapy. 2

Flow Rates and Settings

  • Flow range: 30–70 L/min 2
  • Initial settings: 40–50 L/min (range 35–60 L/min for adults) 2
  • Temperature: 34–37°C 2
  • FiO₂ titrated to achieve target SpO₂ (94–98% or 88–92% for hypercapnic-risk patients) 2

Physiologic Benefits (Moderate-Certainty Evidence)

  • Delivers up to 60 L/min airflow, matching inspiratory demand 2
  • Provides reliable FiO₂ up to 100% 2
  • Generates low-level PEEP (~7 cmH₂O at 50 L/min) 2
  • Supplies heated humidification, improving comfort and secretion clearance 2
  • Reduces CO₂ washout of upper airways 2

Clinical Outcomes (Moderate Certainty)

  • May reduce intubation rates (risk ratio 0.89; 95% CI 0.77–1.02) 2
  • Similar short-term mortality to conventional oxygen (RR 0.99; 95% CI 0.84–1.17) 2
  • Significantly improves patient comfort versus reservoir masks 2
  • Lowers respiratory rate by mean 2.25 breaths/min 2
  • Increases PaO₂ by mean 16.7 mmHg 2
  • Reduces re-intubation risk (4.9% vs 12.2%; p = 0.04) 2

Special Population

  • Especially beneficial for immunocompromised patients due to lower risk of ventilator-associated pneumonia 2

High-Concentration Reservoir (Non-Rebreather) Mask

Flow Rates and FiO₂ Delivery

  • Flow rate: 15 L/min delivering 60–90% FiO₂ 2
  • Preferred initial method for severe hypoxemia in critically ill patients 2

Clinical Algorithm

  • Start with reservoir mask at 15 L/min for severe hypoxemia 2
  • Adjust downward to nasal cannula or simple face mask once target saturation (94–98%) is achieved 2

Specialized Oxygen Delivery Systems

Oxygen-Conserving Devices

These devices deliver oxygen only during inspiration, reducing oxygen consumption by up to 50%. 1, 5

Types

  • Transtracheal catheters 5
  • Reservoir cannulas 5
  • Demand oxygen delivery systems 5

Mechanism

  • Deliver oxygen only during inspiratory phase, minimizing waste during expiration 2, 5
  • Transtracheal catheters increase effective FiO₂ by approximately 5% per liter (compared to 2.5% per liter with nasal cannula) 6

Indications

  • Ambulatory patients requiring high flow rates 1
  • Patients active outside the home 1
  • Only after formal ambulatory oxygen assessment 1

Limitations

  • Variable ability to maintain target SaO₂ during exercise 1
  • Mouth-breathing patients may fail to trigger the device 1
  • Pre-prescription assessment is mandatory 1

Trans-Tracheal Oxygen

Trans-tracheal oxygen is rarely used in home settings and requires dedicated support from a trained team. 1

Mechanism

  • Oxygen delivered via catheter inserted percutaneously between second and third tracheal rings 1
  • Reduces anatomical dead space, allowing lower oxygen flow rates than nasal cannula 1, 2
  • Reduces work of breathing 1, 2

Serious Complications

  • Catheter displacement 1, 2
  • Obstruction by mucus 1, 2
  • Infection 1, 2

Oxygen via Tracheostomy

Delivery Method

  • Tracheostomy collar is most widely used 1
  • Most centers advocate enhanced humidification 1

Critical Requirement

  • Patients receiving oxygen via tracheostomy MUST receive humidified oxygen to maintain patent airway, reduce secretion buildup, and minimize discomfort 1

Face Tents and Head Hoods

Disadvantages

  • Limit mobility and visibility of patient 1
  • CO₂ can build up with insufficient flow rates 1
  • Temperature and moisture buildup 1
  • These problems complicate widespread usage 1

Oxygen Delivery System Selection

Source Options

  • Compressed gas cylinders 1
  • Liquid oxygen 1
  • Oxygen concentrators 1

Selection Criteria

  • Flow and concentration of oxygen needed 1
  • Equipment availability from local vendors 1
  • Insurance coverage 1

Humidification Guidelines

When Humidification is NOT Required

  • Low-flow oxygen (nasal cannula or masks) 2
  • Short-term high-flow use (e.g., pre-hospital) 2

When Humidification is Indicated

  • High-flow oxygen systems used >24 hours 2
  • Patients reporting upper-airway dryness 2
  • Patients with tracheostomy or artificial airways 1, 2
  • Viscous secretions (may add nebulized saline) 2
  • HFNC always includes heated humidification as part of the system 2

What to Avoid

  • Bubble bottles (oxygen bubbling through water) should be avoided—they provide no clinical benefit and pose infection risk 2

Clinical Decision Algorithm for Hypoxemia

Mild-to-Moderate Hypoxemia

  1. Start with nasal cannula at 1–4 L/min (24–40% FiO₂) 2
  2. Target SpO₂ 94–98% for most patients 2
  3. Adjust flow based on pulse oximetry 2

Severe Hypoxemia

  1. Start with high-concentration reservoir mask at 15 L/min 2
  2. Consider HFNC if hypoxemia persists without hypercapnia 2
  3. Prepare for intubation if non-invasive methods fail 2

Hypercapnic-Risk Patients (COPD, Obesity Hypoventilation)

  1. Use Venturi mask at 24% or 28% OR nasal cannula at 1–2 L/min 2
  2. Target SpO₂ 88–92% (NOT 94–98%) 2, 4
  3. At 6 L/min via nasal cannula, hypercapnia can develop within 15 minutes 4
  4. When precise FiO₂ control is unavailable, limit high-flow oxygen to maximum 6 minutes 4

Monitoring and Escalation

Monitoring Parameters

  • Pulse oximetry (SpO₂) 2
  • Arterial blood gas when indicated 2
  • Respiratory rate 2
  • Work of breathing 2

Escalation Pathway

  1. Nasal cannula (1–6 L/min) 2
  2. Simple face mask (5–10 L/min) OR Venturi mask (for precise FiO₂) 2
  3. High-concentration reservoir mask (15 L/min) 2
  4. High-flow nasal cannula (30–70 L/min) 2
  5. Non-invasive positive pressure ventilation (CPAP/BiPAP) 2
  6. Endotracheal intubation and mechanical ventilation 2

Safety Considerations and Common Pitfalls

Critical Safety Points

  • Never use simple face mask below 5 L/min—causes dangerous CO₂ rebreathing 2
  • Verify correct wall-outlet connections—mis-connecting oxygen tubing to compressed-air outlets has caused adverse events 2
  • During nebulizer treatments, maintain prescribed oxygen delivery and keep SpO₂ within target range 2

Common Pitfalls to Avoid

  • Do NOT assume nasal cannula delivers a consistent FiO₂—the same flow rate can have widely different effects in different patients 2, 4
  • Do NOT assume nasal cannula is ineffective in mouth breathers—mouth breathing often increases delivered oxygen concentration 4, 3
  • Do NOT target SpO₂ 94–98% in hypercapnic-risk patients—target 88–92% instead 2, 4

Special Circumstances: Traveling with Oxygen

Altitude and Airline Travel

  • Commercial aircraft maintain cabin altitudes between 6,000–8,000 feet 1
  • At 8,000 feet, inspired PO₂ is 118 mmHg (versus 159 mmHg at sea level) 1
  • Patients on supplemental oxygen will require enhanced FiO₂ at altitude 1

Formula to Estimate Required FiO₂

FiO₂ (BP – 47) [ground level] = FiO₂ (BP – 47) [altitude] 1

  • BP = barometric pressure in mmHg 1

Practical Recommendations

  • Contact airline well in advance 1
  • Attempt to utilize direct flights 1
  • Arrange oxygen availability between flights for oxygen-dependent patients 1
  • Hypoxic challenge testing (15–16% inspired oxygen) can predict effect of airline travel 1

Transporting Oxygen in Vehicles

  • Cylinders should be secured with seat belt, or in foot-well or car boot 1
  • Liquid oxygen must always be transported upright 1
  • Warning triangle may be displayed 1
  • Insurance companies should be informed 1

Portable Oxygen Equipment

  • Trolleys or wheeled devices improve quality of life, distance walked, and symptoms in patients who can walk >300 meters 1
  • Less able patients find trolleys easier to use than backpacks 1

Device Performance at Varying Respiratory Rates

Variable Performance Systems (Nasal Cannula, Simple Face Mask)

  • Deliver significantly reduced oxygen concentration at high respiratory rates 7

Fixed Performance Systems (Venturi Masks)

  • Deliver appropriate oxygen concentrations across range of respiratory rates for 24–40% settings 7
  • 60% Venturi masks show reduction in performance at high respiratory rates 7

High-Flow Systems

  • Show no failure of performance at increased respiratory rates 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Respiratory Oxygen Delivery Methods

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Oxygen Therapy with Nasal Cannula and Other Methods

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

FiO2 Delivered by Nasal Cannula

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

[Oxygen-conserving devices: a forgotten resource].

Archivos de bronconeumologia, 2007

Related Questions

What oxygen delivery devices should be used for different FiO₂ requirements and respiratory statuses?
What are the steps to write an oxygen order?
What is the estimated FiO2 (fraction of inspired oxygen) for a patient on 4 liters of oxygen via a simple mask?
How does the fraction of inspired oxygen (FiO2) change with the amount of oxygen administered in liters per minute (L/min)?
What FiO₂ should be set for adult patients on supplemental oxygen or mechanical ventilation to achieve a target peripheral oxygen saturation of 92‑96% (or arterial PaO₂ 60‑80 mm Hg), considering conditions such as chronic hypercapnic respiratory failure or severe hypoxemia?
Which of the following is NOT used in the treatment of sarcoidosis: corticosteroids, hydroxychloroquine, vitamin D, anti‑TNF agents, or methotrexate?
In a kidney‑transplant recipient with biopsy‑proven BK virus nephropathy and persistent high BK viremia despite reduction of immunosuppression, can intravenous immunoglobulin (IVIG) be used, and what is the recommended dosing protocol?
Which statements are true about pulmonary ANCA-associated vasculitis: a) In asthmatic patients, eosinophilic granulomatosis with polyangiitis onset precedes asthma exacerbation; b) Churg‑Strauss syndrome (eosinophilic granulomatosis with polyangiitis) typically shows peripheral blood eosinophilia >10%; c) Exophthalmos raises suspicion for Wegener’s granulomatosis (granulomatosis with polyangiitis); d) Wegener’s granulomatosis is limited to the lower airways, sparing the upper airways; e) Eosinophilic granulomatosis with polyangiitis is associated with c‑ANCA positivity?
In a patient with an acute cerebellar infarction due to vertebral‑artery dissection, should beta‑blockers be initiated for blood pressure management?
Which of the following are chronic causes of disseminated intravascular coagulation (DIC): viral infections, vascular aneurysms, graft rejection, neoplasms, or placental abruption?
In a kidney‑transplant recipient with BK virus nephropathy, should intravenous immunoglobulin (IVIG) be used as first‑line therapy, and what dosing regimen is recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.